Oliver Illini

Vienna, 1210, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Clinical Impact of EGFR Mutation Subtypes on Treatment Outcomes in Advanced Non-Small Cell Lung Cancer: An Austrian Real-World Study.

Clinical Impact of EGFR Mutation Subtypes on Treatment Outcomes in Advanced Non-Small Cell Lung Cancer: An Austrian Real-World Study.

Journal: Cancers

Published: November 29, 2025

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 13, 2025

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 13, 2025

Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysis.

Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysis.

Journal: NPJ precision oncology

Published: September 05, 2025

Multidisciplinary treatment of advanced or metastatic ALK-positive non-small cell lung cancer: Real-world data on Brigatinib combined with local therapy.

Multidisciplinary treatment of advanced or metastatic ALK-positive non-small cell lung cancer: Real-world data on Brigatinib combined with local therapy.

Journal: Medicine

Published: April 28, 2025

Prognostic Value of PD-L1, BAP-1 and ILK in Pleural Mesothelioma.

Prognostic Value of PD-L1, BAP-1 and ILK in Pleural Mesothelioma.

Journal: Journal of clinical medicine

Published: October 31, 2024

Sleep-Disordered Breathing in Patients with Chronic Heart Failure and Its Implications on Real-Time Hemodynamic Regulation, Baroreceptor Reflex Sensitivity, and Survival.

Sleep-Disordered Breathing in Patients with Chronic Heart Failure and Its Implications on Real-Time Hemodynamic Regulation, Baroreceptor Reflex Sensitivity, and Survival.

Journal: Journal of clinical medicine

Published: October 29, 2024

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report.

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report.

Journal: Cancer treatment and research communications

Published: October 26, 2024

Adenosquamous Carcinoma of the Lung: Survival, Radiologic Findings, PD-L1, and Driver Mutations.

Adenosquamous Carcinoma of the Lung: Survival, Radiologic Findings, PD-L1, and Driver Mutations.

Journal: Journal of clinical medicine

Published: August 24, 2024

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 12, 2024

Neoadjuvant therapy in early-stage non-small cell lung cancer: A real-world analysis.

Neoadjuvant therapy in early-stage non-small cell lung cancer: A real-world analysis.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 30, 2024

Prognostic impact of targetable driver alterations in resected early-stage lung cancer.

Prognostic impact of targetable driver alterations in resected early-stage lung cancer.

Journal: Translational lung cancer research

Published: May 16, 2024

Showing 1-12 of 26

Last Updated: 09/26/2026